+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 171 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
S

Actively Recruiting

Researchers are evaluating new treatments for follicular lymphoma FL, a type of cancer. This trial studies the combination of a new immunotherapy drug, MK-1045, with rituximab, a targeted therapy, compared to the usual treatment of rituximab combined with chemotherapy. The goal is to assess safety, tolerability, cancer response, and how long participants live without disease progression. Participants receive escalating doses of MK-1045 once weekly for up to about 12 months along with rituximab every 4 weeks for up to 6 months. In a comparison group, participants receive standard chemotherapy options chosen by their doctor plus rituximab for up to 4 to 6 months depending on the regimen. The study includes two parts a dose-finding phase and a randomized phase to compare treatments. During the study, participants undergo regular monitoring for side effects and treatment response over several years. Evaluations include imaging to measure cancer, laboratory tests, and questionnaires about quality of life. The main outcomes measured are adverse events, treatment discontinuation due to side effects, cancer remission rates, progression-free survival, and overall survival. Follow-up lasts up to around 5 years after treatment starts.

Age: 18Years +All GendersPhase 2Phase 3
35 locations
C

Actively Recruiting

Researchers are evaluating new treatment options for people aged 12 and older with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia B-ALL. The study compares an investigational immunotherapy called MK-1045 with a standard immunotherapy named blinatumomab. The trial aims to determine whether MK-1045 leads to a higher rate of complete remission and longer overall survival compared to blinatumomab. The study has two parts Part 1 focuses on finding the best dose of MK-1045, where participants receive either a lower or higher dose once weekly for up to 13 cycles that include both 28-day and 42-day periods. Part 2 randomizes participants to receive the chosen dose of MK-1045 or blinatumomab, which is given on days 1, 8, 15, and 22 of each 42-day cycle. Participants may also receive premedications like acetaminophen, diphenhydramine, and dexamethasone, and rescue medications if needed. Throughout the trial, participants undergo regular assessments including bone marrow tests to check for cancer remission, monitoring for side effects, and evaluations of overall survival lasting up to approximately 7 years. Researchers track outcomes such as complete remission rates, adverse events, and duration of treatment response. Participants will have scheduled visits during treatment cycles and follow-up periods to monitor their health and the study treatments effects.

Age: 12Years +All GendersPhase 2Phase 3
28 locations
L

Actively Recruiting

Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.

Age: 18Years +All GendersPhase 3
118 locations
L

Actively Recruiting

Researchers are studying the long-term safety of ciltacabtagene autoleucel cilta-cel, a CAR-T therapy targeting B-cell maturation antigen in patients previously treated for multiple myeloma. The goal is to collect data on delayed side effects and better understand the long-term risks associated with cilta-cel treatment. This study is a phase 4 trial sponsored by Janssen Research & Development, LLC. Participants in this study do not receive any new treatment. Instead, the study monitors individuals who had previously received cilta-cel in company-sponsored clinical trials. The study is divided into two phases the first five years after the last cilta-cel dose, and years six to fifteen after that dose. Follow-up evaluations are conducted at least once per year to check for any delayed adverse events. During the study, participants undergo safety assessments including reviews of adverse events, laboratory tests, physical and neurological examinations. Researchers track outcomes such as new malignancies, neurological or autoimmune disorders, serious infections, and other serious adverse events over a period of up to 15 years. This long-term follow-up helps characterize the safety profile of cilta-cel after treatment completion.

Age: 18Years +All GendersPhase 4
50 locations
S

Actively Recruiting

Researchers are studying ASTX030, a combination of azacitidine and cedazuridine, alone or with venetoclax in people with myeloid neoplasms including myelodysplastic syndromes MDS, chronic myelomonocytic leukemia CMML, and acute myeloid leukemia AML. This multi-phase study includes phases 1 through 3 for monotherapy and phases 1 and 2 for combination therapy, aiming to evaluate the safety, pharmacokinetics, and effectiveness of these treatments over approximately 8 years. Participants receive various treatments depending on the study phase and arm. Treatments include oral doses of azacitidine, cedazuridine, ASTX030, subcutaneous azacitidine, and venetoclax in different sequences and cycles, typically lasting 28 days each. Some phases involve dose escalation and expansion stages, while others compare oral and subcutaneous forms or combine ASTX030 with venetoclax. Participants in certain arms may cross over to other treatments later in the study. During the study, participants undergo regular assessments including blood tests to measure drug levels, DNA methylation, and response rates such as complete remission. Researchers track adverse events, survival outcomes, transfusion independence, and pharmacokinetics up to 36 months or longer depending on the phase. Safety monitoring includes up to 24 months for some arms. The study involves scheduled visits for dosing and evaluations, with ongoing data collection to understand treatment effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
73 locations
S

Actively Recruiting

This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.

Age: 50Years - 80YearsAll GendersPhase 2
140 locations
S

Actively Recruiting

Researchers are studying bleximenib, a drug being evaluated for treating acute leukemia in this Phase 12 clinical trial. The study aims first to find the recommended dose of bleximenib that is safe and tolerable in adults and children with relapsed or refractory acute leukemia. The later phase will assess how well bleximenib works at that dose to fight leukemia. Participants in the early part of the study will receive increasing oral doses of bleximenib to identify safe levels. Then, more participants will take the recommended dose to confirm safety and learn about the drugs effects. In the Phase 2 part, participants will continue to take bleximenib orally at the recommended dose to evaluate its ability to induce remission and assess safety. During the study, participants will be monitored for side effects and response to treatment for up to nearly five years. Researchers will measure safety by tracking adverse events and dose-limiting toxicities in Phase 1, and remission rates in Phase 2. Blood tests, plasma drug levels, and assessments of leukemia response will be performed regularly. The study will also evaluate overall survival, event-free survival, and transfusion independence as important outcomes.

Age: 2Years +All GendersPhase 1Phase 2
102 locations
P

Actively Recruiting

Researchers are evaluating IDP-121, a new drug targeting the cMyc protein, in patients with relapsed or refractory blood cancers including multiple myeloma, diffuse large B-cell lymphoma, high-grade B-cell lymphomas, and chronic lymphocytic leukemia. This open-label, multicenter Phase 12 study aims first to find the highest safe dose and recommended dose for further study, then to assess how well patients respond to the drug and how long those responses last. In the Phase 1 dose-escalation phase, patients receive IDP-121 by 4-hour intravenous infusion twice weekly on specific days within 28-day cycles. Doses start low and increase based on safety and tolerance, with monitoring for dose-limiting toxicities during the first treatment cycle. Once the recommended Phase 2 dose is identified, additional patients enter the expansion phase to further assess safety and effectiveness, receiving treatment for up to 12 cycles or until progression or unacceptable side effects. Participants will undergo regular monitoring including blood tests, heart function assessments, and evaluations of their disease status throughout treatment. Researchers will measure outcomes such as overall response rate, duration of response, and progression-free survival. The study allows treatment to continue up to one year, with careful tracking of safety and disease progression, aiming to gather comprehensive data on IDP-121s impact in these blood cancers.

Age: 18Years +All GendersPhase 1Phase 2
11 locations
P

Actively Recruiting

Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
193 locations

1-10 of 171

1